Fig. 1From: Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studiesCONSORT flow diagram. Dose of AFM11 by cohort (cycle 1 week 1, cycle 1 week 2 onward) was as follows: cohort 1, 0.0007 μg/kg/week, 0.002 μg/kg/week; cohort 2, 0.002 μg/kg/week, 0.006 μg/kg/week; cohort 3, 0.007 μg/kg/week, 0.02 μg/kg/week; cohort 4, 0.02 μg/kg/week, 0.06 μg/kg/week; cohort 5, 0.06 μg/kg/week, 0.18 μg/kg/week; cohort 6, 0.13 μg/kg/week, 0.4 μg/kg/weekBack to article page